Janux Therapeutics Inc. (JANX)
28.92
0.12 (0.42%)
At close: Apr 14, 2025, 3:59 PM
29.33
1.40%
After-hours: Apr 14, 2025, 05:17 PM EDT
0.42% (1D)
| Bid | 27 |
| Market Cap | 1.71B |
| Revenue (ttm) | 10.59M |
| Net Income (ttm) | -68.99M |
| EPS (ttm) | -1.28 |
| PE Ratio (ttm) | -22.59 |
| Forward PE | -18.85 |
| Analyst | Buy |
| Ask | 29.7 |
| Volume | 723,509 |
| Avg. Volume (20D) | 1,087,742.1 |
| Open | 29.09 |
| Previous Close | 28.80 |
| Day's Range | 27.78 - 29.18 |
| 52-Week Range | 22.52 - 71.71 |
| Beta | 3.27 |
About JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 11, 2021
Employees 81
Stock Exchange NASDAQ
Ticker Symbol JANX
Website https://www.januxrx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for JANX stock is "Buy." The 12-month stock price forecast is $70, which is an increase of 142.05% from the latest price.
Stock ForecastsNext Earnings Release
Janux Therapeutics Inc. is scheduled to release its earnings on May 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+11.64%
Janux Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
4 months ago
+48.98%
Janux Therapeutics shares are trading higher after the company announced updated interim clinical data for its JANX007 program in prostate cancer.
